Skip to main content
SpringerLink
Log in

Pharmacotherapy for Conjunctival Malignancies

  • Chapter
  • First Online:
Clinical Ophthalmic Oncology

  • 457 Accesses

Abstract

Medical therapy for ocular malignancies is an expanding field with increasing options for ocular surface malignancies. Epithelial, lymphoproliferative, and pigmented lesions of the conjunctiva now all have pharmacologic therapeutic options at the clinician’s disposal. Topical chemotherapy drops of interferon alpha-2b (IFNα-2b), 5-fluorouracil, and mitomycin have shown promising results as a primary therapy for ocular surface squamous neoplasia (OSSN). They have also been used as adjuvants to surgical excision. While these agents are the main medical agents for OSSN, retinoic acid, aloe vera, cidofovir, and anti-vascular endothelial growth factor have been tried with some success.

Pharmacological therapy for ocular and adnexal lymphoma is dependent on whether the disease is localized (unilateral or bilateral) or systemic. Local therapy has traditionally been radiotherapy, but local injections of rituximab and interferon have shown some success in small series. Systemic disease is treated with systemic chemotherapies, including monoclonal antibodies and radio-tagged monoclonal agents.

Pigmented lesions of the conjunctiva are life threatening, and surgery remains the mainstay of treatment. In cases of unresectable disease, and as adjuvants, medical therapies are needed. Mitomycin has an effect against pigmented cells. While imperfect, it reduces ocular surface pigmentation. The use of IFNα-2b has been reported with less success. Novel checkpoint inhibitors targeting programed cell death 1 (PD-1), such as pembrolizumab, have shown early potential for pigmented lesions of the ocular surface, but additional data is needed to understand their role in conjunctival melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pe’er J. Ocular surface squamous neoplasia. Ophthalmol Clin N Am. 2005;18(1):1–13, vii.

    Google Scholar 

  2. Murillo JC, Galor A, Wu MC, Kye NK, Wong J, Ahmed IO, et al. Intracorneal and intraocular invasion of ocular surface squamous neoplasia after intraocular surgery: report of two cases and review of the literature. Ocul Oncol Pathol. 2017;3(1):66–72.

    PubMed  Google Scholar 

  3. McClellan AJ, McClellan AL, Pezon CF, Karp CL, Feuer W, Galor A. Epidemiology of ocular surface squamous neoplasia in a veterans affairs population. Cornea. 2013;32(10):1354–8.

    PubMed  PubMed Central  Google Scholar 

  4. Gichuhi S, Sagoo MS, Weiss HA, Burton MJ. Epidemiology of ocular surface squamous neoplasia in Africa. Tropical Med Int Health. 2013;18(12):1424–43.

    Google Scholar 

  5. Nanji AA, Mercado C, Galor A, Dubovy S, Karp CL. Updates in ocular surface tumor diagnostics. Int Ophthalmol Clin. 2017;57(3):47–62.

    PubMed  PubMed Central  Google Scholar 

  6. Sayed-Ahmed IO, Palioura S, Galor A, Karp CL. Diagnosis and medical management of ocular surface squamous neoplasia. Expert Rev Ophthalmol. 2017;12(1):11–9.

    CAS  PubMed  Google Scholar 

  7. Sepulveda R, Pe’er J, Midena E, Seregard S, Dua HS, Singh AD. Topical chemotherapy for ocular surface squamous neoplasia: current status. Br J Ophthalmol. 2010;94(5):532–5.

    PubMed  Google Scholar 

  8. Adler E, Turner JR, Stone DU. Ocular surface squamous neoplasia: a survey of changes in the standard of care from 2003 to 2012. Cornea. 2013;32(12):1558–61.

    PubMed  Google Scholar 

  9. Pe’er J. Ocular surface squamous neoplasia: evidence for topical chemotherapy. Int Ophthalmol Clin. 2015;55(1):9–21.

    PubMed  Google Scholar 

  10. Tsatsos M, Karp CL. Modern management of ocular surface squamous neoplasia. Expert Rev Ophthalmol. 2014;8(3):287–95.

    Google Scholar 

  11. Houglum JE. Interferon: mechanisms of action and clinical value. Clin Pharm. 1983;2(1):20–8.

    CAS  PubMed  Google Scholar 

  12. Shah SU, Kaliki S, Kim HJ, Lally SE, Shields JA, Shields CL. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification. Arch Ophthalmol (Chicago III: 1960). 2012;130(2):159–64.

    CAS  Google Scholar 

  13. Karp CL, Galor A, Chhabra S, Barnes SD, Alfonso EC. Subconjunctival/perilesional recombinant interferon alpha2b for ocular surface squamous neoplasia: a 10-year review. Ophthalmology. 2010;117(12):2241–6.

    PubMed  Google Scholar 

  14. Vann RR, Karp CL. Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia11The authors have no proprietary interest in the development or marketing of any drug mentioned in this article. Ophthalmology. 1999;106(1):91–7.

    CAS  PubMed  Google Scholar 

  15. Galor A, Karp CL, Chhabra S, Barnes S, Alfonso EC. Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study. Br J Ophthalmol. 2010;94(5):551–4.

    CAS  PubMed  Google Scholar 

  16. Rishi P, Shields CL. Intralesional and topical interferon therapy following incomplete primary excision of ocular surface squamous neoplasia. Indian J Ophthalmol. 2016;64(6):460–1.

    PubMed  PubMed Central  Google Scholar 

  17. Arnaud P. Different interferons: pharmacology, pharmacokinetics, proposed mechanisms, safety and side effects. Rev Med Interne. 2002;23(4):449s–58s.

    PubMed  Google Scholar 

  18. Aldave AJ, Nguyen A. Ocular surface toxicity associated with topical interferon alpha-2b. Br J Ophthalmol. 2007;91(8):1087–8.

    PubMed  PubMed Central  Google Scholar 

  19. Yeatts PR, Engelbrecht N, Curry CD, Ford JG, Walter KA. 5-Fluorouracil for the treatment of tntraepithelial neoplasia of the conjunctiva and cornea. Am Acad Ophthalmol. 2000;107(12):2191–5.

    Google Scholar 

  20. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8.

    CAS  PubMed  Google Scholar 

  21. Joag MG, Sise A, Murillo JC, Sayed-Ahmed IO, Wong JR, Mercado C, et al. Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia. Ophthalmology. 2016;123(7):1442–8.

    PubMed  PubMed Central  Google Scholar 

  22. Parrozzani R, Lazzarini D, Alemany-Rubio E, Urban F, Midena E. Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study. Br J Ophthalmol. 2011;95(3):355–9.

    PubMed  Google Scholar 

  23. Midena E, Angeli CD, Valenti M, de Belvis V, Boccato P. Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. Br J Ophthalmol. 2000;84:268–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Venkateswaran N, Mercado C, Galor A, Karp CL. Comparison of topical 5-fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia. Am J Ophthalmol. 2018.

    Google Scholar 

  25. Yeatts RP, Ford JG, Stanton CA, Reed JW. Topical 5-fluorouracil in treating epithelial neoplasia of the conjunctiva and cornea. Ophthalmology. 1995;102(9):1338–44.

    CAS  PubMed  Google Scholar 

  26. Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anti-Cancer Drugs. 1990;1:5–13.

    CAS  PubMed  Google Scholar 

  27. Singh P, Singh A. Mitomycin-c use in ophthalmology. IOSR J Pharm. 2013;3(1):12–4.

    Google Scholar 

  28. Frucht-Pery J, Sugar J, Baum J, Sutphin JE, Pe’er J, Savir H, et al. Mitomycin C treatment for conjunctival—corneal intraepithelial neoplasia. Ophthalmology. 1997;104(12):2085–93.

    CAS  PubMed  Google Scholar 

  29. Shields CL, Naseripour M, Shields JA. Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol. 2002;133(5):601–6.

    CAS  PubMed  Google Scholar 

  30. Blasi MA, Maceroni M, Sammarco MG, Pagliara MM. Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study. Eur J Ophthalmol. 2018;28(2):204–9.

    PubMed  Google Scholar 

  31. Siganos CS, Kozobolis VP, Christodoulakis EV. The intraoperative use of mitomycin-c in excision of ocular surface neoplasia with or without limbal autograft transplantation. Cornea. 2002;21(1):12–6.

    PubMed  Google Scholar 

  32. Prabhasawat P, Tarinvorakup P, Tesavibul N, Uiprasertkul M, Kosrirukvongs P, Booranapong W, et al. Topical 0.002% mitomycin C for the treatment of conjunctival corneal intraepithelial neoplasia and squamous cell carcinoma. Cornea. 2005;24(4):443–8.

    PubMed  Google Scholar 

  33. Ballalai PL, Erwenne CM, Martins MC, Lowen MS, Barros JN. Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia. Ophthalmic Plast Reconstr Surg. 2009;25(4):296–9.

    PubMed  Google Scholar 

  34. Quebbeman EJ, Hoffman NE, Ausman RK, Hamid AA. Stability of mitomycin admixtures. Am J Hosp Pharm. 1985;42(8):1750–4.

    CAS  PubMed  Google Scholar 

  35. Chen C, Louis D, Dodd T, Muecke J. Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia. Br J Ophthalmol. 2004;88:17–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Frucht-Pery J, Rozenman Y, Pe’er J. Topical mitomycin-C for partially excised conjunctival squamous cell carcinoma. Ophthalmology. 2002;109(3):548–52.

    PubMed  Google Scholar 

  37. Abraham LM, Selva D, Casson R, Leibovitch I. Mitomycin: clinical applications in ophthalmic practice. Drugs. 2006;66(3):321–40.

    CAS  PubMed  Google Scholar 

  38. Lichtinger A, Pe’er J, Frucht-Pery J, Solomon A. Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia. Ophthalmology. 2010;117(3):431–7.

    PubMed  Google Scholar 

  39. Tunc M, Erbilen E. Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma. Am J Ophthalmol. 2006;142(4):673–5.

    CAS  PubMed  Google Scholar 

  40. Billing K, Karagiannis A, Selva D. Punctal-canalicular stenosis associated with mitomycin-C for corneal epithelial dysplasia. Am J Ophthalmol. 2003;136(4):746–7.

    PubMed  Google Scholar 

  41. Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev. 2010;62(13):1285–98.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Klaassen I, Braakhuis BJM. Anticancer activity and mechanism of action of retinoids in oral and pharyngeal cancer. Oral Oncol. 2002;38:532–42.

    CAS  PubMed  Google Scholar 

  43. Muindi JRF, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW, et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 1992;52:2138–42.

    CAS  PubMed  Google Scholar 

  44. Herbort CP, Zografos L, Zwingli M, Schoeneieh M. Topical retinoic acid in dysplastic and metaplastic keratinization of corneoconjunctival epithelium. Graefes Arch Clin Exp Ophthalmol. 1988;226:22–6.

    CAS  PubMed  Google Scholar 

  45. Krilis M, Tsang H, Coroneo M. Treatment of conjunctival and corneal epithelial neoplasia with retinoic acid and topical interferon alfa-2b: long-term follow-up. Ophthalmology. 2012;119(10):1969–73.

    PubMed  Google Scholar 

  46. Nanji AA, Sayyad FE, Karp CL. Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol. 2013;24(4):336–42.

    PubMed  Google Scholar 

  47. Skippen B, Tsang H, Assaad N, Coroneo M. Rapid response of refractory ocular surface dysplasia to combination treatment with topical all-trans retinoic acid and interferon alfa-2b. Arch Ophthalmol. 2010;128(10):1368–9.

    PubMed  Google Scholar 

  48. Harlev E, Nevo E, Lansky EP, Ofir R, Bishayee A. Anticancer potential of aloes: antioxidant, antiproliferative, and immunostimulatory attributes. Planta Med. 2012;78(9):843–52.

    CAS  PubMed  Google Scholar 

  49. Damani MR, Shah AR, Karp CL, Orlin SE. Treatment of ocular surface squamous neoplasia with topical aloe vera drops. Cornea. 2015;34(1):87–9.

    PubMed  Google Scholar 

  50. Zabawski EJJ, Cockerell CJ. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J Am Acad Dermatol. 1998;39(5):741–5.

    PubMed  Google Scholar 

  51. Snoeck R, Wellens W, Desloovere C, Ranst MV, Neaesens L, De Clercq E, et al. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine]. J Med Virol. 1998;54:219–25.

    CAS  PubMed  Google Scholar 

  52. Sherman M, Feldman K, Farahmand S, Margolis TP. Treatment of conjunctival squamous cell carcinoma with topical cidofovir. Brief Rep. 2002;134(3):432–3.

    CAS  Google Scholar 

  53. Asena L, Dursun Altinors D. Topical bevacizumab for the treatment of ocular surface squamous neoplasia. J Ocul Pharmacol Ther. 2015;31(8):487–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Kim LA, D’Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol. 2012;181(2):376–9.

    PubMed  PubMed Central  Google Scholar 

  55. Finger PT, Chin KJ. Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study. Ophthalmic Plast Reconstr Surg. 2012;28(2):85–9.

    PubMed  Google Scholar 

  56. Paul S, Stone DU. Intralesional bevacizumab use for invasive ocular surface squamous neoplasia. J Ocul Pharmacol Ther. 2012;28(6):647–9.

    CAS  PubMed  Google Scholar 

  57. Faramarzi A, Feizi S. Subconjunctival bevacizumab injection for ocular surface squamous neoplasia. Cornea. 2013;32(7):998–1001.

    PubMed  Google Scholar 

  58. Pozarowska D, Pozarowski P. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol. 2016;41(3):311–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Hartmann EM, Ott G, Rosenwald A. Molecular biology and genetics of lymphomas. Hematol Oncol Clin North Am. 2008;22(5):807–23, vii.

    PubMed  Google Scholar 

  60. Sassone M, Ponzoni M, Ferreri AJ. Ocular adnexal marginal zone lymphoma: clinical presentation, pathogenesis, diagnosis, prognosis, and treatment. Best Pract Res Clin Haematol. 2017;30(1–2):118–30.

    PubMed  Google Scholar 

  61. Shields CL, Shields JA. Conjunctival lymphoid tumors clinical analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology. 2001;108:979–84.

    CAS  PubMed  Google Scholar 

  62. Viani GA, Fendi LI. Adjuvant treatment or primary topical monotherapy for ocular surface squamous neoplasia: a systematic review. Arq Bras Oftalmol. 2017;80(2):131–6.

    PubMed  Google Scholar 

  63. Blasi MA, Tiberti AC, Valente P, Laguardia M, Sammarco MG, Balestrazzi A, et al. Intralesional interferon-alpha for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results. Ophthalmology. 2012;119(3):494–500.

    PubMed  Google Scholar 

  64. Lachapelle KR, Rathee R, Kratky V, Dexter DF. Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon alfa-2b. Arch Ophthalmol (Chicago, III: 1960). 2000;118:284–5.

    CAS  Google Scholar 

  65. Cerny T, Borisch B, Introna M, Johnson P, Rose A. Mechanism of action of rituximab. Anti-Cancer Drugs. 2002;13(Suppl 2):3–10.

    Google Scholar 

  66. Sein J, Stefanovic A, Karp CL. Diagnosis and treatment of conjunctival lymphoma. EyeNet. 2012;16(9):41-43. https://www.aao.org/eyenet/article/diagnosis-treatment-of-conjunctival-lymphoma.

  67. Annibali O, Chiodi F, Sarlo C, Cortes M, Quaranta-Leoni FM, Quattrocchi C, et al. Rituximab as single agent in primary MALT lymphoma of the ocular adnexa. Biomed Res Int. 2015;2015:895105.

    PubMed  PubMed Central  Google Scholar 

  68. Tuncer S, Tanyildiz B, Basaran M, Buyukbabani N, Dogan O. Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: single institution experience. Curr Eye Res. 2015;40(8):780–5.

    CAS  PubMed  Google Scholar 

  69. Ferreri AJ, Govi S, Colucci A, Crocchiolo R, Modorati G. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas. Ophthalmology. 2011;118(1):24–8.

    PubMed  Google Scholar 

  70. Demirci H, Kauh CY, Rajaii F, Elner VM. Intralesional rituximab for the treatment of recurrent ocular adnexal lymphoma. Ophthalmic Plast Reconstr Surg. 2017;33(3S Suppl 1):S70–S1.

    PubMed  Google Scholar 

  71. Biotti D, Lerebours F, Bonneville F, Ciron J, Clanet M, Brassat D. Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder. Mult Scler. 2018:1352458518765677.

    Google Scholar 

  72. Yi JH, Kim SJ, Ahn HK, Lee SJ, Chang MH, Kim WS. Rituximab-induced acute thrombocytopenia: a case report and review of the literature. Med Oncol. 2009;26(1):45–8.

    PubMed  Google Scholar 

  73. Oellers P, Savar A, Samaniego F, Pro B, Esmaeli B. Second-line 90Yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab. Ophthalmic Plast Reconstr Surg. 2012;28(6):e145–6.

    PubMed  Google Scholar 

  74. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, et al. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol. 2009;20(4):709–14.

    CAS  PubMed  Google Scholar 

  75. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20(15):3262–9.

    CAS  PubMed  Google Scholar 

  76. Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med. 2000;27(7):766–77.

    CAS  PubMed  Google Scholar 

  77. Govi S, Dognini GP, Licata G, Crocchiolo R, Resti AG, Ponzoni M, et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol. 2010;150:226–48.

    PubMed  Google Scholar 

  78. Ferreri AJ, Sassone M, Kiesewetter B, Govi S, Scarfo L, Donadoni G, et al. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. Ann Oncol. 2015;26(8):1760–5.

    CAS  PubMed  Google Scholar 

  79. Peters DH, Clissold SP. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992;44(1):117–64.

    CAS  PubMed  Google Scholar 

  80. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010;299(3):C539–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Han JJ, Kim TM, Jeon YK, Kim MK, Khwarg SI, Kim CW, et al. Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. Ann Hematol. 2015;94(4):575–81.

    CAS  PubMed  Google Scholar 

  82. Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006;98(19):1375–82.

    CAS  PubMed  Google Scholar 

  83. Bryant SG, Fisher S, Kluge RM. Increased frequency of doxycycline side effects. Pharmacotherapy. 1987;7(4):125–9.

    CAS  PubMed  Google Scholar 

  84. Jakobiec FA, Folberg R, Iwamoto T. Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmology. 1989;96(2):147–66.

    CAS  PubMed  Google Scholar 

  85. Damato BE, Coupland SE. Ocular melanoma. Saudi J Ophthalmol. 2012;26(2):137–44.

    PubMed  PubMed Central  Google Scholar 

  86. Shields CL, Shields JA. Tumors of the conjunctiva and cornea. Surv Ophthalmol. 2004;49(1):3–24.

    PubMed  Google Scholar 

  87. Shields CL, Markowitz JS, Belinsky I, Schwartzstein H, George NS, Lally SE, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology. 2011;118(2):389–95 e1–2.

    PubMed  Google Scholar 

  88. Wong JR, Nanji AA, Galor A, Karp CL. Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol. 2014;9(3):185–204.

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Kurli M, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience. Graefes Arch Clin Exp Ophthalmol. 2005;243(11):1108–14.

    CAS  PubMed  Google Scholar 

  90. Pe’er J, Frucht-Pery J. The treatment of primary acquired melanosis (PAM) with atypia by topical Mitomycin C. Am J Ophthalmol. 2005;139(2):229–34.

    PubMed  Google Scholar 

  91. Finger PT, Czechonska G, Liarikos S. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol. 1998;82:476–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Chalasani R, Giblin M, Conway RM. Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment. Clin Exp Ophthalmol. 2006;34(7):708–14.

    PubMed  Google Scholar 

  93. Huerva V, Traveset AE, Vilardell F. Topical interferon alpha-2b for diffuse conjunctival primary acquired melanosis with atypia. Ocul Immunol Inflamm. 2017;25(2):284–6.

    PubMed  Google Scholar 

  94. Finger PT, Sedeek RW, Chin KJ. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol. 2008;145(1):124–9.

    CAS  PubMed  Google Scholar 

  95. Garip A, Schaumberger MM, Wolf A, Herold TR, Miller CV, Klingenstein A, et al. Evaluation of a short-term topical interferon alpha-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia. Orbit. 2016;35(1):29–34.

    PubMed  Google Scholar 

  96. Herold TR, Hintschich C. Interferon alpha for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol. 2010;248(1):111–5.

    CAS  PubMed  Google Scholar 

  97. Oellers P, Karp CL. Management of pigmented conjunctival lesions. Ocul Surf. 2012;10(4):251–63.

    PubMed  Google Scholar 

  98. Bratton EM, Knutsen-Larson S, Durairaj VD, Gregory DG, Mellette JR. Combination topical therapy for conjunctival primary acquired melanosis with atypia and periocular lentigo maligna. Cornea. 2015;34(1):90–3.

    PubMed  Google Scholar 

  99. Kini A, Fu R, Compton C, Miller DM, Ramasubramanian A. Pembrolizumab for recurrent conjunctival melanoma. JAMA Ophthalmol. 2017;135(8):891–2.

    PubMed  Google Scholar 

  100. Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy systemic indications and ophthalmic side effects. Retina. 2018;38:1063–78.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, FL, USA

    Ghada Al Bayyat, Dan Arreaza-Kaufman, Anat Galor & Carol L. Karp

  2. Ocular Oncology Service and Ophthalmic Pathology Laboratory, Department of Ophthalmology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel

    Jacob Pe’er

Authors
  1. Ghada Al Bayyat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dan Arreaza-Kaufman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anat Galor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jacob Pe’er
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carol L. Karp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol L. Karp .

Editor information

Editors and Affiliations

  1. Ocular Onocology Service and Ophthalmic Pathology Laboratory, Department of Ophthalmology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel

    Jacob Pe'er

  2. Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA

    Arun D. Singh

  3. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

    Bertil E. Damato

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Al Bayyat, G., Arreaza-Kaufman, D., Galor, A., Pe’er, J., Karp, C.L. (2019). Pharmacotherapy for Conjunctival Malignancies. In: Pe'er, J., Singh, A., Damato, B. (eds) Clinical Ophthalmic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-06046-6_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-06046-6_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-06045-9

  • Online ISBN: 978-3-030-06046-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation